Novel Biomarkers for Heart Disease

• Autore: Lichtenauer Michael
• Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
• Descrizione fisica: 1 online resource (420 p.)
• Soggetto topico: Medicine
• Soggetto non controllato: acute kidney injury; acute myocardial infarction; AMI; aneurysm; aortic disease; aortic regurgitation; atrial fibrillation; atrial myopathy; biomarker; biomarkers; carbohydrate antigen-125; cardiac biomarkers; cardiac intensive care units; cardiac magnetic resonance imaging; cardiometabolic disease; cardiometabolic risks; cardiovascular death; cardiovascular diseases; cardiovascular events; cardiovascular risk; cardiovascular surgery; catestatin; cell adhesion molecule; ceramides; ceruloplasmin; chronic heart failure; chronic kidney disease; circulating cells; circulating miRNAs; CKD; cohort studies; coronary artery disease; CVD; diet quality; echocardiography; ejection fraction; epicardial adipose tissue; epicardial fat; epicardial fat volume; FABP3; fatty acid-binding protein 3; Framingham risk score; GDF-15; GDF8; growth differentiation factor 15 (GDF-15); H-FABP; healthy eating index; heart failure; heart failure decompensation; heart-type fatty acid-binding protein; heart-type fatty acid-binding protein (H-FABP); herat failure; HF; HFpEF; HFrEF; hypertension; inflammatory marker; KLF4; left ventricular adverse remodelling; left ventricular ejection fraction; left ventricular systolic function; liver-type fatty-acid-binding protein; long-term outcomes; longitudinal strain; magnetic resonance imaging; magnetic resonance spectroscopy; metabolic syndrome; microRNA; miRNA; mitochondrial DNA (mtDNA); mitochondrial dysfunction; muscle wasting; myocardial infarction; myocardial triglyceride content; myostatin; n/a; NAFLD; NAFLD fibrosis score; NT-proBNP; NYHA functional class; obesity; older women; operative risk; oxidative stress; PBMCS; Pentraxin-3; platelets; PPCI; pregnancy-associated plasma protein-A; primary prevention; reactive oxygen species (ROS); renal dysfunction; repeated measurements; risk prediction; risk stratification; saliva; salivary biomarkers; sarcopenia; secondary prevention; SOCE; soluble suppression of tumorigenicity 2 (sST2); soluble urokinase-type plasminogen activator receptor (suPAR); sST2; STEMI; STIM1; sudden cardiac death; suPAR; synthetic phenotype; T1 mapping; TGF-β pathway; thyroid-stimulating hormone; troponin; vena contracta area; ventricular arrhythmia; ventricular tachycardia; very low-density lipoprotein
• Persona (resp. second.): LichtenauerMichael
• Sommario/riassunto: Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.
• Titolo autorizzato: Novel Biomarkers for Heart Disease
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910557546203321
• Lo trovi qui: Univ. Federico II